Sai Parenterals Ltd (SAIPARENT) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Sai Parenterals Ltd on NSE and BSE, with an AI summary of each filing.
Audio recording of earning call held on 2nd November, 2026 over call.
Audio / Video · 03 Nov 2026, 2:20 am
Sai Parenterals Releases Audio Recording for Q2 Earnings Call Sai Parenterals Limited has made available the audio recording of its post-earnings group conference call for Q2 ended 30th Sep'26, which was held on 2nd Nov'26. The access link has been published on the company's website pursuant to Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
Investor Presentation for the quarter and half year ended 30th September, 2026
Investor Presentation · 02 Nov 2026, 1:43 am
Sai Parenterals Reports Robust Q2FY27 Results and Advances Major Expansion Capex Sai Parenterals delivered Q2FY27 consolidated revenue of Rs. 196.1 cr (up 9.0% QoQ, 257.4% YoY) with EBITDA surging 67.4% QoQ to Rs. 41.4 cr and PAT reaching Rs. 10.5 cr. H1FY27 revenue hit Rs. 376.0 cr against its full-year FY27 target of Rs. 750 cr. The company completed acquisitions of 60% stakes in Saicriti Pharma (Rs. 83.83 cr) and Sai Prathyak Laboratories (Rs. 15.0 cr) on 5th Oct'26, utilizing reallocated IPO proceeds. Ongoing Rs. 571 cr group capex remains on track, targeting EU-GMP/USFDA-ready injectable scale by Jul'27.
Investor press release on standalone and consolidated unaudited financial results for the quarter ended 30th September, 2026.
Press Release · 01 Nov 2026, 11:48 pm
Sai Parenterals Q2FY27 Results: Operational Margins Expand on Capacity and Portfolio Additions Sai Parenterals reported Q2FY27 consolidated revenue of Rs. 196.1 crore, rising 9.0% QoQ, driven by operational efficiencies that expanded gross margin to 47.5%. EBITDA surged 67.4% QoQ to Rs. 41.4 crore with margins at 21.1%, while PAT reached Rs. 10.5 crore despite higher depreciation. H1FY27 revenue stood at Rs. 376.0 crore, tracking at 50% of the full-year Rs. 750 crore target. Unit III expansion completed, boosting monthly capacity by 81% to 155 million units, alongside acquiring 60% stakes in Saicriti Pharma and Sai Prathyak Laboratories.
Statement of variation and deviation for the period ended 30th September, 2026
Others (Uncategorized) · 01 Nov 2026, 11:37 pm
Sai Parenterals Reports Nil Deviation in IPO Proceeds Utilization for Sep'26 Quarter Sai Parenterals confirmed zero deviation or variation in utilizing proceeds from its ₹2,850 million IPO for the quarter ended 30th Sep'26, as monitored by India Ratings & Research. Key fund deployments include ₹356.41 million for subsidiary bridge and term loan repayments, ₹330.00 million for working capital, and ₹284.90 million for issue expenses. The company allocated ₹838.34 million (₹100 million utilized) for a 60% equity stake in Saicriti Pharma to construct an injectable facility, alongside ₹150 million utilized for a 60% stake in Prathyak Laboratories.
Financial Results
Financial Result · 01 Nov 2026, 9:34 pm
Sai Parenterals Q2 FY27 Consolidated Results and Corporate Actions Sai Parenterals reported consolidated Q2 revenue from operations of ₹1,949.18 mn for the quarter ended 30th Sep'26, up 264.1% YoY from ₹535.28 mn and 9.1% QoQ from ₹1,786.72 mn. Profit after tax rose 65.5% YoY to ₹105.10 mn (Q1: ₹79.23 mn), with EPS at ₹2.38. The board approved acquiring the remaining 25% stake in SP Analytics for ₹25,000 to make it a wholly owned subsidiary by 31st Dec'26, and confirmed completing the 60% stake acquisition in Saicriti Pharma.
Sai Parenterals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 01 Nov 2026, 8:39 pm
Unaudited financial results for the quarter and half-year ended September, 30th 2026.
Financial Result · 01 Nov 2026, 8:28 pm
Outcome of Board Meeting held on 1st November, 2026
Outcome · 01 Nov 2026, 8:22 pm
Sai Parenterals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 1,949 (+264.1% YoY | +9.1% QoQ) ■ EBITDA: 402 (+252.3% YoY | +71.1% QoQ) ■ EBITDA Margin (%): 20.6 (-69 bps YoY | +748 bps QoQ) ■ PAT: 105 (+65.5% YoY | +32.7% QoQ) ■ EPS (INR): 2.38 (+395.8% YoY | +33.0% QoQ)
Schedule of Q2 of FY 2026-27 Earnings Conference Call.
Intimation · 02 Nov 2026, 2:00 pm
Sai Parenterals Schedules Q2 and 1H FY27 Earnings Conference Call Sai Parenterals Limited will host an earnings conference call on 2nd Nov'26 at 2:00 PM IST to discuss its operational and financial performance for Q2 and 1H FY27. Organized by Emkay Global Financial Services, the call will feature senior management, including Chairman & Managing Director Anil KK and Noumed CEO Mark Thulborne. Dial-in access is available via universal numbers (+91 22 6280 1325 / +91 22 7115 8226) alongside international toll-free connections.
Sai Parenterals Limited has informed the Exchange about Board Meeting to be held on 01-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 01 Nov 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 01 Nov 2026, 5:30 am
Sai Parenterals Limited has informed the Exchange about Board Meeting to be held on 01-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 01 Nov 2026, 5:30 am
Sai Parenterals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/11/2026 ,inter alia, to consider and approve unaudited financial results ....
Intimation · 01 Nov 2026, 5:30 am
Sai Parenterals Board to Consider Q2 FY27 Results on 1st November 2026 Sai Parenterals Limited has scheduled a Board of Directors meeting on 1st Nov'26 to consider and approve the standalone and consolidated un-audited financial results along with the limited review report for the quarter and half-year ended 30th Sep'26. Additionally, the trading window for dealing in company securities remains closed for all designated persons and their immediate relatives until 48 hours after the declaration of the financial results.
Media release about the acquisition.
Press Release · 05 Oct 2026, 9:12 pm
Sai Parenterals Acquires 60% Stake in Prathyak Laboratories for Rs 15 Crore On 5th Oct'26, Sai Parenterals completed the acquisition of a 60% equity stake in Hyderabad-based R&D center Prathyak Laboratories for Rs. 15 crore, funded via unutilized IPO proceeds. The acquisition replaces its planned greenfield R&D facility, adding 28 scientists and a pipeline of 150 SKUs across 86 molecules in complex and oncology injectables. Sai Parenterals holds a Right of First Refusal to acquire the remaining 40% at the same valuation via internal accruals, strengthening its regulated-market injectable franchise and Australia-New Zealand supply commitments.
Monitoring agency report for the quarter ended 30 June 2026
Others (Uncategorized) · 03 Oct 2026, 5:30 pm
India Ratings Flags INR 238.74 Million IPO Proceed Deviations for Sai Parenterals India Ratings & Research reported up to 10% deviation (INR 238.74 mn) in Sai Parenterals' INR 2,850 mn fresh IPO proceeds for the quarter ended 30th Jun'26. Key deviations include INR 149.21 mn in general corporate purposes commingled in common operating accounts, INR 69.72 mn paid to the BRLM without supporting documentation (later refunded), INR 14.25 mn unutilized same-day transfers for capacity expansion, and INR 1.28 mn in interest servicing. Total unutilized proceeds stood at INR 1,447.73 mn, primarily deployed in bank fixed deposits.
Intimation of Schedule of Analyst / Institutional Investor meetings under Regulation 30 (read with Para A of Part A of Schedule III) of SEBI (Listing Obligations and Disclosure Requirements) ....
Intimation · 01 Oct 2026, 10:56 pm
Sai Parenterals Schedules Analyst and Institutional Investor Meeting in Hyderabad Sai Parenterals Limited announced that company officials will host an institutional investor and analyst meeting at its facilities in Hyderabad on 14th Oct'26, starting at 11:00 AM. The company confirmed that interactions will rely strictly on publicly available information, with no unpublished price-sensitive information (UPSI) being discussed.
Outcome of the Board Meeting
Change in Management · 30 Sept 2026, 5:35 pm
Sai Parenterals Appoints New COO and Company Secretary Sai Parenterals Limited approved the appointment of Mr. Arvind Gannimitta as Chief Operating Officer and Mr. Ashwani Singh Bisht as Company Secretary and Compliance Officer (KMP), both effective 30th Sep'26. Mr. Gannimitta holds a Ph.D. in Pharmaceuticals with over 26 years of operational and manufacturing experience, while Mr. Bisht brings over 12 years of professional secretarial and compliance experience. Concurrently, the Board accepted the resignation of Ms. Shivali Aggarwal from the role of Company Secretary and Compliance Officer, effective 30th Sep'26, citing personal reasons.
Board Meeting Appointment of Mr. Ashwani Singh Bisht CS and Mr. Arvind as COO.
Others (Uncategorized) · 30 Sept 2026, 5:31 pm
Sai Parenterals Appoints New Chief Operating Officer and Company Secretary Sai Parenterals Limited's Board of Directors approved key leadership changes effective 30th Sep'26. The company appointed Dr. Arvind Gannimitta as Chief Operating Officer, bringing over 26 years of pharmaceutical operations and manufacturing expertise. Additionally, Ashwani Singh Bisht was appointed as Company Secretary and Compliance Officer (Key Managerial Personnel), leveraging over 12 years of professional experience in corporate secretarial functions. These appointments follow the resignation of former Company Secretary and Compliance Officer Shivali Aggarwal, which took effect on 30th Sep'26 due to personal reasons.
Scrutinizers Report and Voting Results for the 25th Annual General Meeting held on 10th September, 2026.
Annual General Meeting · 10 Sept 2026, 10:09 pm
Outcome of 25th Annual General Meeting held on 10th September, 2026.
Annual General Meeting · 10 Sept 2026, 10:07 pm
Announcement under Regulation 30 (LODR)
Press Release · 26 Aug 2026, 12:08 am
Sai Parenterals Renews Key Australian OTC Supply Agreement Sai Parenterals’ Australian subsidiary, Noumed Pharmaceuticals, has renewed its OTC supply agreement with a leading pharmacy network. The 3-year deal, valued at AUD 30 million (approx. INR 204 crores), expands the product portfolio and secures long-term revenue. This, combined with a 7.5-year agreement renewed on 1st Jul'26, brings the total contracted Australian OTC book to AUD 232 million (approx. INR 1,506 crores). Production will progressively shift in-house from third-party manufacturers, converting distribution margins into higher manufacturing margins and improving earnings visibility.
Announcement under Regulation 30 (LODR)
Others (Uncategorized) · 26 Aug 2026, 12:06 am
Sai Parenterals Unit Renews Key Australian Supply Agreement Valued at Rs. 204 Cr Sai Parenterals’ subsidiary, Noumed Pharmaceuticals, renewed its long-term OTC Medicines Supply Agreement with a leading Australian pharmacy chain. The 3-year contract, effective 24th Aug'26, is valued at AUD 30 million (approx. Rs. 204 Cr) and features an expanded product portfolio. The agreement is with an international, non-related party and represents a significant renewal with a higher value. The contract may be terminated with 6 months' notice prior to expiry.
Intimation of schedule of Analyst/Institutional Investors Meeting scheduled to be held on 31st August, 2026
Intimation · 25 Aug 2026, 10:48 pm
Sai Parenterals Schedules Institutional Investor Meeting in Mumbai Sai Parenterals Limited (NSE: SAIPARENT) will conduct a physical group meeting with analysts and institutional investors on 31st Aug'26, starting at 10:00 AM in Mumbai. The event is hosted by Strategic Growth Advisors Pvt. Ltd. Discussions will be limited to publicly available information, with no unpublished price-sensitive information (UPSI) being shared. The schedule is subject to change.
Book closure intimation for 25th Annual General Meeting
Annual General Meeting · 19 Aug 2026, 11:30 pm
Annual Report of the company for FY 2025-26
Others (Uncategorized) · 19 Aug 2026, 11:28 pm